Stock AMRX AMNEAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Real-time Estimate Cboe BZX
Other stock markets
 15:07:43 09/05/2024 BST 		5-day change 1st Jan Change
6.635 USD +0.68% Intraday chart for Amneal Pharmaceuticals, Inc. +7.09% +9.56%
05-06 Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating MT
05-03 Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amneal Reports First Quarter 2024 Financial Results
AQ
Amneal Pharmaceuticals : First Quarter 2024 Earnings Presentation
PU
Amneal: Q1 Earnings Snapshot
AQ
Amneal Reports First Quarter 2024 Financial Results
BU
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
AQ
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
BU
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine
AQ
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
BU
Amneal to Report First Quarter 2024 Results on May 3, 2024
BU
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful
AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.
PU
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
BU
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Amneal: Q4 Earnings Snapshot
AQ
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
BU
Amneal to Participate at Upcoming Investor Conference
BU
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
AQ
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. News Amneal Pharmaceuticals, Inc.
  5. Press Releases